Eris Lifesciences stated that its consolidated net profit increased 12 per cent to Rs 101 crore for the third quarter ended December 2021.
The company stated that the revenue stood at Rs 332 crore in the third quarter of the current fiscal as against Rs 310 crore in the year-ago period, Eris Lifesciences said.
''Our focus on building leadership brands in fast-growing therapies coupled with several patent expiration opportunities will enable us to sustain our growth trajectory,'' stated Eris Lifesciences Chairman & Managing Director Amit Bakshi.
(With inputs from PTI)
NMIA Takes Off Today As Navi Mumbai International Airport Begins Commercial Operations, Making MMR India’s First Dual-Airport System
A Tale Of 2 Tarmacs: How NMIA Is Changing Mumbai’s Aviation Skyline
Bombay HC Slams Authorities Over Kanjurmarg Dumping Ground Stench, Orders Immediate Scientific Measures
‘BMC Not Doing Anything, Turning A Blind Eye’: Bombay HC Warns Against Granting New Construction Permissions Amid Air Pollution Crisis
